ERBB2 and breast carcinoma: However, HER2 has been found to be overexpressed in a quarter of breast cancers and is connected to higher malignancy, relapse rates, and mortality (Hudis 2007; Kiessling et al.2002; Meric-Bernstam and Hung 2006; Slamon et al.1987).